NCT06868264Phase 3Completed

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Study sponsor: Atea Pharmaceuticals, Inc. · AVIR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-18Actual
Enrollment · participants940Actual
Source updated2026-10-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 880 participants (planned). After: 940 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 18 Jun 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview